Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 1/20 | 0.31 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.31 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.31 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL584717 | 0.79 | ALDH1A1 (0.33) | CASP3SENP8SENP7SENP6CYP1A2 | |
| SCHEMBL585506 | 0.77 | — | — | |
| SCHEMBL584326 | 0.76 | SMN1; SMN2 (0.31) | — | |
| Bromide SCHEMBL6377320 | 0.74 | ALDH1A1 (0.34) | CASP3SENP8SENP7SENP6ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL584577 | 0.73 | SPNS2 (0.32) | — | |
| SCHEMBL584270 | 0.73 | L3MBTL1 (0.31) | — | |
| SCHEMBL13072621 | 0.71 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL2380058 | 0.71 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL1568019 | 0.71 | JAK2 (0.33) | — | |
| Ammonia Solution, Strong SCHEMBL1567873 | 0.69 | JAK2 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101568542-B | 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives | ACTELION PHARMACEUTICALS LTD | 2013-03-27 | — | — | CN | disclosed |
| US-8188082-B2 | 5,6,7,8-tetrahydro-imidazo[1,5-α]pyrazine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-05-29 | — | — | US | disclosed |
| EP-2125823-B1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-02-15 | — | — | EP | disclosed |
| CN-102076694-A | 5, 6, 7, 8-tetrahydro-imidazo[1, 5-a]pyrazine compounds | ACTELION PHARMACEUTICALS LTD | 2011-05-25 | — | — | CN | disclosed |
| US-20110105514-A1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-05-05 | — | — | US | disclosed |
| EP-2307417-A2 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE COMPOUNDS | Actelion Pharmaceuticals Ltd. (CH) | 2011-04-13 | — | — | EP | disclosed |
| US-20100093740-A1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-04-15 | — | — | US | disclosed |
| WO-2009156951-A2 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-12-30 | — | — | WO | disclosed |
| EP-2125823-A1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2009-12-02 | — | — | EP | disclosed |
| CN-101568542-A | 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2009-10-28 | — | — | CN | disclosed |
| WO-2008078291-A1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105514-A1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE COMPOUNDS | HCRTR1, HCRTR2, NPY5R | CASP3 3312/4885SENP8 2940/4885SENP7 2471/4885 |
| US-20100093740-A1 | 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE DERIVATIVES | HCRTR1, HCRTR2, NPY5R | CASP3 2846/4885SENP8 3951/4885SENP7 3789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.